Biomarkers of Alcohol After an Experimental Administration of Alcohol Simulating a "Binge Drinking" Episode

Alcohol-Related Disorders Clinical Trial

— BINGE  

Official title:

Biomarkers of Acute Damage and Exposure/Consumption to Alcohol After an Experimental Administration of Alcohol Simulating a "Binge Drinking" Episode in Young Adults

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03931018
• Other study ID #: HUGTP/BINGE/PNSD/1
• Status: Recruiting
• Phase: N/A
• Start date: December 1, 2017
• Est. completion date: March 1, 2020

Study information

• Verified date: April 2019
• Source: Fundació Institut Germans Trias i Pujol
• Contact: Angels Fortes, BS
• Phone: 34 93 497 89 56
• Email: ceic.germanstrias[@]gencat.cat
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purposes of this study are 1) to determine the pharmacokinetics of alcohol after experimental administration of alcohol simulating a "binge-drinking" episode in young adults 2) to determine the profile of biomarkers of acute damage and exposure/consumption to alcohol 3) to determine the pharmacokinetic parameters and evaluate the acute effects alcohol and its relationship with biomarkers.

Description:

Binge drinking (BD) has become trendy among adolescents and young adults. It is defined as a pattern of drinking that reach blood alcohol concentration (BAC) to 80 mg/dl in a short period of time (2 hours), that typically occurs after 4 drinks for women and 5 drinks for men. Despite its high prevalence and association with morbidity and mortality, there are no previous experimental studies evaluating alcohol concentrations after a "binge drinking" episode neither its effects on biomarkers of acute damage and exposure/consumption.

The aims of this study are 1) to determine the pharmacokinetics of alcohol after experimental administration of alcohol simulating a "binge-drinking" episode in young adults 2) to determine the profile of biomarkers of acute damage and exposure/consumption to alcohol 3) to determine the pharmacokinetic parameters and evaluate the acute effects alcohol and its relationship with biomarkers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: March 1, 2020
• Est. primary completion date: December 31, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Understanding and accepting the study procedures and signing the informed consent.

• Male and females healthy volunteers (18-35 years old)

• Clinical history and physical examination demonstrating no organic or psychiatric disorders.

• The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically.

• Body weight between 60 and 85 kilograms for men and between 50 and 65 kg in for women. Lower or higher weights will be accepted, if the researchers considered that do not pose a risk to the subjects and do not interfere with the objectives of the study.

• BMI between 19-27 kg/m². Lower or higher BMIs will be allow, if the researchers considered that do not pose a risk to the subjects and do not interfere with the objectives of the study.

• Recreational use of alcohol at least 1 standard unit alcohol (standard drink)/day (accumulated in the week) and previous experiences in drunkenness and binge-drinking.

• Women with a regular menstrual cycle lasting between 26-32 days.

Exclusion Criteria:

• Not fill the inclusion criteria.

• History or clinical evidence of gastrointestinal, liver, renal or other disorders which may lead to suspecting a disorder in drug absorption, distribution, metabolism or excretion, or that suggest gastrointestinal irritation due to drugs.

• Present history of substance use disorder according to Diagnostic and Statistical Manual for Mental Disorders (DSM)-IV (except for nicotine). Past history of mild substance use disorder (corresponding to abuse substance according to DSM-IV) could be included.

• Blood donation 8 weeks before or participation in other clinical trials with drugs in the previous 12 weeks.

• Having suffered any organic disease or major surgery in the three months prior to the study start.

• Subjects with intolerance or serious adverse reactions to alcohol. Asian subjects with no intolerance or serious adverse reactions to alcohol could be included.

• Regular use of any drug in the month prior to the study sessions.The treatment with single or limited doses of symptomatic medicinal products in the week prior to the study sessions will not be a reason for exclusion if it is calculated that it has been cleared completely the day of the experimental session.

• Daily consumption >10 cigarettes.

• Daily consumption >20 grams of alcohol in women and >40 grams of alcohol in men.

Daily consumption >5 coffees, tea, cola refreshment or other stimulating drinks or containing xanthines in the three months prior to the study start.

• Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed.

• Subjects with positive serology to Hepatitis B, C or HIV.

• Pregnant, breastfeeding women or those not use an method of contraception or not use an effective contraceptive (i.e. abstinence, intrauterine devices, barrier methods or partner vasectomy).

Related Conditions & MeSH terms

• Alcohol-Related Disorders
• Binge Drinking
• Binge-Eating Disorder

Intervention

Other:
• Alcohol
Administration of one dose of alcohol among two possible different doses (in males) or only one possible dose (in females) simulating a binge drinking episode under experimental conditions.

Locations

Country	Name	City	State
Spain	Hospital Universitari Germans Trias i Pujol-Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (HUGTP-IGTP)	Badalona	Barcelona

Sponsors (2)

Lead Sponsor	Collaborator
Fundació Institut Germans Trias i Pujol	Germans Trias i Pujol Hospital

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area Under the Concentration-Time Curve (AUC 0-24h) of alcohol concentration in blood.	Calculation of AUC of the concentrations of alcohol in blood.	From pre-dose (baseline, 0 hours) to 0.33 hours (h), 0.66 h, 1.33 h, 1.66 h, 2 h, 2.33 h, 2.66 h, 3 h, 3.5 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h and 24 h post-dose.
Secondary	Area Under the Concentration-Time Curve (AUC 0-24h) of biomarkers of acute damage and exposure/consumption in blood.	Calculation of AUC of the concentrations of other biomarkers of exposure/consumption in blood.	From pre-dose (base-line, 0 hour), to 2.33 hour (h), 4 h, 6 h, 8 h, 24 h post-dose. Additional samples will be collected at 7,14 and 21 days post-administration
Secondary	Cumulative amount of biomarkers of exposure/consumption excreted into urine up to collection time of last measurable concentration.	Urine will be collected in intervals and the total amount of biomarkers of exposure/consumption will be calculated (ethylglucuronide and ethylsulfate)	From pre-dose (base-line, 0 hours (h)) and following intervals 0-2h, 2-4h, 4-6h, 6-8h, 8-10h, 10-12h and 12-24h to 24h post-administration
Secondary	Elimination half-life f the concentrations of alcohol in blood.	Calculation of elimination half-life of the concentrations of alcohol in blood.	From pre-dose (baseline, 0 hours) to 0.33 h, 0.66 h, 1.33 h, 1.66 h, 2 h, 2.33 h, 2.66 h, 3 h, 3.5 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h and 24 h post-dose
Secondary	Area Under the Concentration-Time Curve (AUC 0-24h) of alcohol in breath (BrAC)	Calculation of AUC of the concentrations of alcohol in breath (BrAC)	From pre-dose (baseline, 0 hours) to 0.33 h, 0.66 h, 1.33 h, 1.66 h, 2 h, 2.33 h, 2.66 h, 3 h, 3.5 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h and 24 h post-dose
Secondary	Change in blood pressure	Blood pressure measured in mmHg	From pre-dose (baseline, 0 hours) to 24 hours post-dose
Secondary	Change in heart rate	Heart rate measured in beats per minute	From pre-dose (baseline, 0 hours) to 24 hours post-dose
Secondary	Change in oral temperature	Oral temperature measured in Celsius degrees	From pre-dose (baseline, 0 hours) to 24 hours post-dose
Secondary	Change in drunkenness	Drunkenness will be measured using rate scales	From pre-dose (baseline, 0 hours) to 24 hours post-dose.
Secondary	Change in subjective effects	Subjective effects will be measured using rate scales	From pre-dose (baseline, 0 hours) to 24 hours post-dose.
Secondary	Number of Participants with Serious and Non-Serious Adverse Events	Collection of adverse effects spontaneously reported by the participants and/or observed by the investigators.	From pre-dose (baseline, 0 hours) to 21 days post-dose.